Timeline

Voting rights breakdown

Declared beneficial owners · 2

A single, collectively filed disclosure: the voting-rights rate applies to the whole group, not to each person.

• Abingworth LLP79.11%
• Joseph Anderson79.11%

Notice details

Beneficial owner

Abingworth LLP

Acquisition and restructuring of convertible bonds. In case the restructuring of the convertible bonds announced by the Company is effected, which is subject to conditions, the bonds are mandatorily convertible into shares at a conversion ratio of 10'000 shares for each bond with a nominal value of CHF 2'500. The percentage indicated in Part 4 (Disclosure of purchase positions, percentage of voting rights) below is based on the current share capital of the Company as per the entry in the commercial register. In case the bond restructuring will be effected, the actual percentage held by the Abinworth group will be lower. - Convertible bonds, warrants and convertible loan notes are directly held by Abingworth Bioventures V L.P., 38 Jermyn Street, London SW1Y 6DN, which is controlled by Abingworth Bioventures V GP L.P., 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ, as general partner. Abingworth Bioventures V GP L.P, in turn, is controlled by Abingworth General Partner V LLP, 38 Jermyn Street, London SW1Y 6DN, as general partner. Abingworth General Partner V LLP, in turn, is controlled by Abingworth Bioventures V GP Limited, 50 Lothian Road, Festival Square, Edinburgh, EH3 9WJ. Abingworth Bioventures V GP Limited, in turn, is controlled by Abingworth LLP, 38 Jermyn Street, London SW1Y 6DN. Certain employee options on shares in the Company are held for the account of Abingworth LLP as the investment manager of Abingworth Bioventures V L.P., by Joseph Anderson, Surrey, UK. - Warrants are directly held by Abingworth Bioequities Master Fund Limited,PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Island, which operates as an integrated investment structure. Abingworth Bioequities Master Fund Limited is fed by (i) Abingworth Bioequities Fund Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands, and by (ii) Abingworth Bioequities Fund L.P., 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801, USA. Abingworth Bioequities Fund Limited is managed by Abingworth LLP, 38 Jermyn Street, London SW1Y 6DN, UK. Abingworth Bioequities Fund L.P is controlled by Abingworth Bioequities GP Limited, PO Box 309, Ugland House, Grand Cayman KY1-1104, Cayman Islands, as general partner. Abingworth Bioequities GP Limited, in turn, is controlled by Abingworth LLP, 38 Jermyn Street, London SW1Y 6DN, UK.